A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Jul 21, 2017

U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia

TOKYO – July 20, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) granted...

Read more about U.S. FDA Grants Orphan-Drug Designation to Astellas for Development of FLT3 Inhibitor Gilteritinib in Acute Myeloid Leukemia
Jul 7, 2017

Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis Agent “Protopic® Ointment” in Japan

Osaka and Tokyo (Japan), July 7, 2017 – Maruho Co., Ltd (“Maruho”, Head Office: Osaka, Japan, President and CEO: Koichi Takagi) and Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo,...

Read more about Maruho Succeeds Marketing Approval for Anti-Atopic Dermatitis Agent “Protopic® Ointment” in Japan
Jul 5, 2017

Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year

Tokyo, July 5, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has been selected for the sixth consecutive year to be included in the...

Read more about Astellas Named to FTSE4Good Sustainability Index for the Sixth Consecutive Year
Jun 30, 2017

Astellas Submits Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

Tokyo, June 30, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the submission of a supplemental New Drug Application (sNDA) to the...

Read more about Astellas Submits Supplemental New Drug Application for mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder
Jun 21, 2017

The Astellas Oncology C³ Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants

The challenge is open to nearly anyone with a tangible, unique idea to improve cancer care

TOKYO – June 20, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the launch of the second year of the Astellas C³ Prize, a...

Read more about The Astellas Oncology C³ Prize Competition Returns for a Second Year; Aims to Inspire and Support Innovative Ideas for Cancer Care with $100,000 in Grants
Jun 9, 2017

Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer

- Amendment accelerates anticipated PROSPER top-line results by two years -

TOKYO and NEW YORK, June 9, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced today the amendment of the protocol...

Read more about Astellas and Pfizer Announce Amendment to Clinical Research Protocol for Phase 3 PROSPER Trial of enzalutamide in Patients with Non-metastatic Castration-Resistant Prostate Cancer
Jun 5, 2017

Kyoto University and Astellas Inaugurate “Alliance Station” with Aim of Realizing Advanced Medical Treatments

Kyoto and Tokyo, June 5, 2017 - Kyoto University (President: Juichi Yamagiwa) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the inauguration of...

Read more about Kyoto University and Astellas Inaugurate “Alliance Station” with Aim of Realizing Advanced Medical Treatments
Jun 1, 2017

Astellas Announces Commitments to GHIT Fund Replenishment

Tokyo, June 1, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, ”Astellas”) today announced that it has committed to supporting the Global Health Innovative Technology Fund...

Read more about Astellas Announces Commitments to GHIT Fund Replenishment
May 31, 2017

Astellas Announces New Global Website Launch

Improving Transparency and Strengthening the Astellas Brand Worldwide

Tokyo, May 31, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the launch of a new global website. In accordance with the company Disclosure...

Read more about Astellas Announces New Global Website Launch
May 23, 2017

ACTION ON FISTULA TO TRANSFORM 4,500 LIVES BY 2020

Tokyo, May 23, 2017 – Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) on International Day to End Obstetric Fistula, Astellas pledges its support to the Fistula...

Read more about ACTION ON FISTULA TO TRANSFORM 4,500 LIVES BY 2020
May 19, 2017

MSD submits application for approval of type-2 diabetes drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor

Tokyo, May 19, 2017 -MSD K.K. (President: Jannie Oosthuizen; “MSD”) and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka; “Astellas”) today announced that MSD has submitted an...

Read more about MSD submits application for approval of type-2 diabetes drug combining selective DPP-4 inhibitor and selective SGLT2 inhibitor
May 18, 2017

Astellas Announces Oncology Portfolio Updates

TOKYO – May 17, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today an update regarding the Company’s diverse oncology portfolio,...

Read more about Astellas Announces Oncology Portfolio Updates
May 17, 2017

Astellas Completes Acquisition of Ogeda SA

Tokyo, May 17, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that it has completed the acquisition of Ogeda SA (formerly named...

Read more about Astellas Completes Acquisition of Ogeda SA
May 15, 2017

Astellas Announces Continuation of Performance-linked Stock Compensation Scheme

Read more about Astellas Announces Continuation of Performance-linked Stock Compensation Scheme
May 11, 2017

Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical Study Protocol 8273-CL-0302

Tokyo, May 11, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the discontinuation of ASP8273 treatment arm in the the late-stage...

Read more about Astellas Announces Decision to Discontinue ASP8273 Treatment and Close Randomization for Clinical Study Protocol 8273-CL-0302
May 11, 2017

The Institute of Medical Science, the University of Tokyo, and Astellas Enter into an Agreement for Expansion of the Scope of Collaborative Research Utilizing Rice-Based Oral Vaccine"MucoRice" Technology

Tokyo, May 11, 2016 - the Institute of Medical Science, the University of Tokyo (Tokyo, Dean: Yoshinori Murakami, “IMSUT”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko...

Read more about The Institute of Medical Science, the University of Tokyo, and Astellas Enter into an Agreement for Expansion of the Scope of Collaborative Research Utilizing Rice-Based Oral Vaccine"MucoRice" Technology
Apr 28, 2017

Transfer of 16 Long-Listed Products in Japan to LTL Pharma: Closing of Asset Purchase Agreement

Tokyo, April 28, 2017 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that Astellas and LTL Pharma Co., Ltd. (Representative Director, Chairman: Sansei Oka,...

Read more about Transfer of 16 Long-Listed Products in Japan to LTL Pharma: Closing of Asset Purchase Agreement
Apr 27, 2017

Astellas Reports Full Year FY2016 Financial Results

Read more about Astellas Reports Full Year FY2016 Financial Results
Apr 27, 2017

Astellas Announces Cancellation of Treasury Shares

Read more about Astellas Announces Cancellation of Treasury Shares
Apr 27, 2017

Changes of Representative Directors and Directors

Read more about Changes of Representative Directors and Directors
Apr 3, 2017

Astellas to Acquire Ogeda SA

-Acquisition Expands Astellas' Late Stage Clinical Pipeline with Fezolinetant-

Read more about Astellas to Acquire Ogeda SA
Mar 28, 2017

Transfer of 16 Long-Listed Products in Japan

Read more about Transfer of 16 Long-Listed Products in Japan
Mar 23, 2017

Notice of Completion of Acquisition of Own Shares (Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Notice of Completion of Acquisition of Own Shares (Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)
Mar 22, 2017

Launch of LINZESS® Tablets 0.25mg in Japan

Tokyo, March 22, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it launched a guanylate cyclase-C (GC-C) receptor agonist, LINZESS®...

Read more about Launch of LINZESS® Tablets 0.25mg in Japan
Mar 1, 2017

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
Feb 28, 2017

Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease

CAMBRIDGE, Mass. and TOKYO, February 28, 2017 -- Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. ("Astellas") today announced they have entered into an exclusive worldwide license agreement...

Read more about Astellas and Affinivax Announce Worldwide Partnership for MAPS Vaccine targeting Pneumococcal Disease
Feb 27, 2017

Kyowa and Astellas enter into an Agreement for Exclusive Distribution and Promotion of Extended-Release Tablets of Quetiapine Fumarate in Japan

Kyowa Pharmaceutical Industry Co., Ltd. (Head office: Yodogawa-ku, Osaka City, President and Representative Director: Ray Tsunoda, hereinafter called “Kyowa”) and Astellas Pharma Inc....

Read more about Kyowa and Astellas enter into an Agreement for Exclusive Distribution and Promotion of Extended-Release Tablets of Quetiapine Fumarate in Japan
Feb 23, 2017

Joint Storage and Transportation of Pharmaceuticals in Hokkaido by Astellas, Takeda, Teva Takeda Pharma and Teva Takeda Yakuhin - Further ensure stable supplies of pharmaceuticals -

Tokyo, February 23, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced that Astellas, Takeda Pharmaceutical Company Limited (President and CEO:...

Read more about Joint Storage and Transportation of Pharmaceuticals in Hokkaido by Astellas, Takeda, Teva Takeda Pharma and Teva Takeda Yakuhin - Further ensure stable supplies of pharmaceuticals -
Feb 8, 2017

Astellas Announces Personnel Changes and Organizational Changes

Read more about Astellas Announces Personnel Changes and Organizational Changes
Feb 8, 2017

Astellas Announces Changes in Management Structure and Global Function

Read more about Astellas Announces Changes in Management Structure and Global Function
Jan 31, 2017

Astellas Executes License Agreement with Auration Biotech for the Development and Commercialization of AU-935

Tokyo, January 31, 2017 – Astellas Pharma Inc. (“Astellas”; Head Office: Tokyo, President and CEO: Yoshihiko Hatanaka) today announced that it executed a license agreement with respect to an...

Read more about Astellas Executes License Agreement with Auration Biotech for the Development and Commercialization of AU-935
Jan 31, 2017

Astellas Announces Acquisition of Own Shares

Read more about Astellas Announces Acquisition of Own Shares
Jan 31, 2017

Astellas Reports the First Nine Months Financial Results of FY2016

Read more about Astellas Reports the First Nine Months Financial Results of FY2016
Jan 30, 2017

Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan

TOKYO & CAMBRIDGE, Mass., Jan. 30, 2017 — Astellas Pharma Inc. (TSE: 4503) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today top-line results indicating that the Phase III...

Read more about Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
Jan 18, 2017

Astellas Announces Participation in Access Accelerated - Builds on Company Commitment to improve Access to Health -

Tokyo, January 18, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced its participation in Access Accelerated, a global, multi-stakeholder...

Read more about Astellas Announces Participation in Access Accelerated - Builds on Company Commitment to improve Access to Health -
Jan 12, 2017

Astellas Launches Second Phase of Global Campaign on CNN

Tokyo, January 12, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) today announces that it will launch the second phase of the ongoing campaign with CNN....

Read more about Astellas Launches Second Phase of Global Campaign on CNN
Jan 10, 2017

Astellas Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs

Tokyo, January 10, 2017 - Astellas Pharma Inc. (TSE:4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) announced that it exercised its right to terminate the agreement executed as of...

Read more about Astellas Terminates Agreement with UMN Pharma for Cell Culture Based Influenza Vaccine Programs
Dec 26, 2016

Notice of Completion of Acquisition of Own Shares

Tokyo, December 26, 2016 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka) announced that it completed acquisition of its own shares, which was resolved by its Board of...

Read more about Notice of Completion of Acquisition of Own Shares
Dec 21, 2016

Astellas Completes Acquisition of Ganymed Pharmaceuticals

Tokyo, December 21, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has completed the acquisition of Ganymed Pharmaceuticals...

Read more about Astellas Completes Acquisition of Ganymed Pharmaceuticals
Dec 20, 2016

AMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB IN JAPAN

TOKYO (Dec. 20, 2016) – Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; General Manager and Representative Director: Mark Tennyson, “Amgen Astellas”) and Astellas Pharma Inc....

Read more about AMGEN ASTELLAS AND ASTELLAS ANNOUNCE SUBMISSION OF APPLICATION FOR INVESTIGATIONAL OSTEOPOROSIS MEDICATION ROMOSOZUMAB IN JAPAN
Dec 20, 2016

Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy

Tokyo, December 20, 2016 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., “Immunomic...

Read more about Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy
Dec 19, 2016

Marketing Approval of LINZESS®, Treatment for Irritable Bowel Syndrome with Constipation in Japan - Provides a new therapeutic option for adult patients suffering from irritable bowel syndrome with constipation (IBS-C) -

Tokyo, December 19, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it obtained a marketing approval for a guanylate cyclase-C (GC-C)...

Read more about Marketing Approval of LINZESS®, Treatment for Irritable Bowel Syndrome with Constipation in Japan - Provides a new therapeutic option for adult patients suffering from irritable bowel syndrome with constipation (IBS-C) -
Dec 15, 2016

Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu), Astellas Pharma Inc. (HQ: Tokyo, Japan; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Co., Ltd. (HQ: Tokyo,...

Read more about Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells
Dec 14, 2016

Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic CastrationResistant Prostate Cancer

Read more about Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide) Capsules in Patients with Metastatic CastrationResistant Prostate Cancer
Dec 12, 2016

Astellas Announces Transfer of Qutenza to Grünenthal

TOKYO and CHERTSEY – 12 December, 2016: Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, “Astellas”), today announced that Astellas Pharma Europe Ltd. (“Astellas Pharma...

Read more about Astellas Announces Transfer of Qutenza to Grünenthal
Dec 8, 2016

Astellas Research & Development Meeting Highlights

- Turning Innovative Science into Value for Patients -

Read more about Astellas Research & Development Meeting Highlights
Dec 7, 2016

Astellas Launches Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan

Tokyo, December 7, 2016 - Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, “Astellas”) announced that it launched Kiklin® Granules 86.2% (generic name: bixalomer,...

Read more about Astellas Launches Kiklin® Granules, a Treatment for Hyperphosphatemia, in Japan
Dec 1, 2016

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Nov 30, 2016

Initiatives to Pursue Operational Excellence

Tokyo, November 30, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) is promoting its strategic goal “Pursuing Operational Excellence” and engaged...

Read more about Initiatives to Pursue Operational Excellence
Nov 18, 2016

Antihypertensive Drug "Micatrio® Combination Tablets"

Nippon Boehringer Ingelheim Co., Ltd. (Head Office: Tokyo; President and Representative Director: Yoshiaki Aono, hereafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office:...

Read more about Antihypertensive Drug "Micatrio® Combination Tablets"

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts